topical lidocaine cream, 4%, is typically used to produce anesthesia 60 minutes after application. 4,6 Our results suggest that the use of microneedle pretreatment can reduce the incubation time to 30 minutes-perhaps even to 10 minutes in more pain-sensitive individuals-to achieve sufficient anesthesia for needle insertion. Our study has several limitations. First, the pain stimulus was needle based and it is not known how laser-or scalpelbased pain would have been altered. Second, our study was limited to men; future studies should include women. Finally, this study evaluated pain on the volar forearms, but pain sensitivity can vary by anatomical site. Because the participants served as their own controls and the anatomical site at each pain assessment had a symmetrically placed control, the role of the site was minimized. The study should be repeated using other anatomical sites.
Association of Dermatology Consultation With Accuracy of Cutaneous Disorder Diagnoses in Hospitalized Patients: A Multicenter Analysis
Limited information exists on the activity and impact of hospitalist dermatology consultative services or the nature of dermatologic issues affecting inpatients across US academic medical centers. [1] [2] [3] [4] We performed a retrospective, Intensive Care Units (ICU), Obstetrics-Gynecology, Pediatrics, Psychiatry, or Neurology, and provided its presumptive diagnoses at the time of request. All final diagnoses rendered by dermatology consultants were made based on clinical history, examination findings, and laboratory testing. If more than 1 diagnosis was identified, the additional diagnoses were also recorded. Dermatologic concern duration was defined as acute if present for 7 days or less, subacute if present for 8 to 30 days, chronic if present for 1 to 11 months, and longstanding if present for 1 year or longer. Agreement between the primary team's and the dermatology team's diagnosis was determined using 4 categories: "agreement," "disagreement," "agreement but identifying at least a second diagnosis on consultation," and "disagreement but identifying at least a second diagnosis on consultation." The frequency of follow-up evaluations, defined as repeat visits by the dermatology attending physician to the patient's bedside, was also recorded. The difference in agreement rate between groups was assessed using a χ 2 test.
P values were 2-sided and considered significant at the .05 level.
Results | Table 1 lists the patient characteristics and diagnoses. A broad spectrum of dermatologic diagnoses was rendered by the inpatient dermatology services, including inflammatory and neoplastic processes. The agreement between the primary team's preliminary diagnosis and actual diagnosis per consulting team and by diagnosis are listed in Table 2 . The most common consulting team was Medicine (n = 939, 56%), followed by Surgery (n = 251, 15%), ICU (n = 195, 12%), and ED (n = 92, 6%). Cellulitis, leg ulceration, and viral infections were the 3 most commonly undiagnosed and misdiagnosed conditions by the referring team. The majority of primary team preliminary diagnoses included "rash"/unknown (n = 814), followed by cellulitis/abscess (n = 115), and "drug rash" (n = 111), whereas the majority of primary diagnoses by the dermatologist included "drug rash" (n = 292), psoriasis/eczema (n = 170) and benign neoplasm (n = 168). Additional cutaneous issues were identified in 298 (18%) of consults. Diagnosis was confirmed by biopsy in 667 (40.2%) patients. Four hundred (30.9%) patients were admitted because of their skin condition while in the remaining cases, the dermatologic issue was found incidentally or developed during hospitalization. The cutaneous issue duration was recorded in 1226 cases and was acute in 640 patients (52.2%), subacute in 241 patients (19.7%), chronic in 212 patients (17.3%), and longstanding in 233 patients (10.8%). Importantly, dermatology consultation changed the final diagnosis in 71% of consultation requests. Dermatology-specific evaluation and treatment recommendations could be rendered in a single consultation visit in 40.4% of cases (n = 498) or with 1 follow-up evaluation in 29.3% (n = 361) of cases.
Discussion | This research demonstrates that dermatology consultation is associated with improved diagnostic accuracy of cutaneous disorders in hospitalized patients and facilitates early appropriate intervention, suggesting a potential approach to improving care. The results highlight the positive impact of hospitalist dermatology care in the hospital and reinforce the validity of this model for dermatology specialty care. 5 The data presented identify potential practice gaps and areas for targeted education on dermatology topics relevant to primary inpatient teams. 
FLT3 Inhibitor-Associated Neutrophilic Dermatoses
Acute myeloid leukemia (AML) is a hematologic malignancy characterized by a disruption in normal hematopoiesis that results in uninhibited myeloblast proliferation. Cutaneous reactions in AML include leukemia cutis, Sweet syndrome, infections, and treatment-related effects. We present 3 cases of FLT3 (OMIM 136351) inhibitor-associated neutrophilic dermatoses (Table) .
Methods | Patients with FLT3-positive AML underwent treatment as part of 2 concurrent institutional review boardapproved clinical trials. If skin lesions were observed during treatment, a dermatologist evaluated the patient as part of standard of care. The University of Pennsylvania Institutional Review Board approved the clinical trials evaluating FLT3 inhibitors for AML. The patients were seen as part of standard of care evaluation of skin and not as part of their study protocol. These patients provided written informed consent to participate in the FLT3 inhibitor clinical trial; dermatologic evaluation was separate from that trial.
Results | S eventy-seven patients were treated w ith FLT3 inhibitors for AML; 3 developed confirmed neutrophilic dermatoses. Patient 1 was a woman in her 40s diagnosed as hav ing c y togenetic ally normal AML complicated by relapsed disease with FLT3 internal tandem duplication (ITD) after induction, consolidation, and stem cell transplantation. Therapy with the FLT3 inhibitor gilteritinib reduced marrow blasts from 80% to 10%. Two months later, the patient developed multiple tender, red subcutaneous nodules on her back and lower extremities (Figure, A) in the absence of progressive leukemia. A skin biopsy revealed neutrophil-predominant lobular panniculitis (Figure, B) . The eruption improved with 60 mg/d of prednisone and prolonged taper. She later died of disease progression. Patient 2 was a man in his 70s diagnosed as having acute erythroleukemia with normal karyotype complicated by relapsed disease with FLT3 ITD after induction. Gilteritinib nearly eliminated peripheral blasts and reduced marrow blasts to 25%. After 2 months, he developed pustulonodules on the cheeks, ears, and scalp ( Figure, C) . Skin biopsy revealed interstitial neutrophil-rich inflammatory infiltrate and clusters of atypical mononuclear cells (Figure,  D) . The eruption improved with topical corticosteroids. Gilteritinib treatment was later stopped because of disease progression.
Patient 3 was a woman in her 60s diagnosed as having FLT3 ITD-positive AML refractory to induction and salvage therapy. Quizartinib eliminated circulating blasts and reduced marrow blasts to less than 5%. Two months later, she developed a tender, red eruption on the neck and arms. A skin biopsy revealed perivascular, interstitial, and perieccrine neutrophilic inflammatory infiltrate and subepidermal edema. Clinical manifestations improved with 50 mg/d of prednisone and prolonged taper. Quizartinib treatment was discontinued given concern for possible FLT3 inhibitorinduced differentiation syndrome. 
